Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.  The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an ...

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.  The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an ...

Core Viewpoint - Zacks Premium provides various tools and resources to help investors make informed decisions and enhance their confidence in stock market investments [1][2]. Zacks Style Scores - The Zacks Style Scores are indicators designed to assist investors in selecting stocks with the highest potential to outperform the market within a 30-day timeframe, rated from A to F based on value, growth, and momentum [3]. Value Score - The Value Style Score identifies attractive and discounted stocks using financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [4]. Growth Score - The Growth Style Score focuses on a company's future prospects and financial health, analyzing projected and historical earnings, sales, and cash flow to identify stocks with sustainable growth [5]. Momentum Score - The Momentum Style Score helps investors capitalize on price trends, utilizing factors like one-week price changes and monthly earnings estimate changes to determine optimal entry points [6]. VGM Score - The VGM Score combines the three Style Scores, providing a comprehensive rating based on value, growth, and momentum, making it a valuable tool alongside the Zacks Rank [7]. Zacks Rank - The Zacks Rank is a proprietary stock-rating model that uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +23.86% since 1988, significantly outperforming the S&P 500 [8][9]. Stock Selection Strategy - To maximize returns, investors should target stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B, while also considering the direction of earnings estimate revisions [11][12]. Company Spotlight: Veralto Corporation - Veralto Corporation, based in Waltham, Massachusetts, specializes in water analytics, treatment, and related services, employing nearly 17,000 people globally [13]. - Currently rated 3 (Hold) by Zacks, Veralto has a VGM Score of B and a Growth Style Score of B, with a projected year-over-year earnings growth of 7.4% for the current fiscal year [14]. - The Zacks Consensus Estimate for Veralto's earnings has increased to $4.20 per share, with an average earnings surprise of +6%, making it a potential candidate for growth investors [14][15].

Core Viewpoint - Masimo (MASI) shares experienced a significant increase of 34.2% to close at $174.69, driven by a definitive acquisition agreement with Danaher Corporation valued at $180 per share, totaling approximately $9.9 billion [1][2]. Company Summary - The acquisition of Masimo by Danaher Corporation is an all-cash transaction, with completion expected in the second half of 2026, pending regulatory approvals and customary closing conditions [2]. - Masimo is projected to report quarterly earnings of $1.43 per share, reflecting a year-over-year decline of 20.6%, with revenues anticipated at $409.06 million, down 31.9% from the previous year [3]. - The consensus EPS estimate for Masimo has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4]. Industry Context - Masimo is categorized under the Zacks Medical - Instruments industry, where UFP Technologies (UFPT) is another player, closing at $246.13 with a recent return of -5.7% over the past month [5]. - UFP Technologies has a consensus EPS estimate of $2.26, unchanged over the past month, representing an 8.1% decline from the previous year [6].

Core Viewpoint - The M&A Class Action Firm is investigating Masimo Corporation regarding its proposed sale to Danaher Corporation, where Masimo shareholders are set to receive $180.00 per share in cash, raising questions about the fairness of the deal [1]. Group 1: Investigation Details - The investigation is led by attorney Juan Monteverde from Monteverde & Associates PC, a firm recognized for recovering millions for shareholders [1]. - The firm is noted for its successful track record in class action securities litigation, including cases in trial and appellate courts [1]. Group 2: Transaction Overview - Under the terms of the proposed transaction, Masimo shareholders will receive $180.00 per share in cash, prompting scrutiny over whether this is a fair deal [1].

Core Viewpoint - Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Masimo Corporation to Danaher Corporation for $180.00 per share in cash, which is perceived as below market expectations and potentially opportunistic [1][2][4]. Group 1: Sale Price Analysis - The proposed sale price of $180.00 per share is significantly lower than the price targets set by several Wall Street analysts, including $210 by Jason Bednar of Piper Sandler, $190 by Vik Chopra of Wells Fargo, and $185 by Jayson Bedford of Raymond James [2]. - The sale price is also below Masimo's 52-week high of $194.88 per share, indicating that the offer may be opportunistic [2]. Group 2: Legal Investigation - Wohl & Fruchter LLP is examining whether the Masimo board acted in the best interests of shareholders in recommending the sale, focusing on the fairness of the sale price and the completeness of information disclosed regarding the transaction [4]. - Shareholders concerned about the fairness of the sale price are encouraged to contact Wohl & Fruchter LLP to discuss their legal rights [3][4].

Core Viewpoint - Halper Sadeh LLC is investigating whether Masimo Corporation is obtaining a fair price for its shareholders in the proposed sale to Danaher Corporation for $180.00 per share in cash [1]. Group 1: Investigation Details - The investigation focuses on whether Masimo and its board of directors violated federal securities laws and/or breached fiduciary duties by failing to obtain the best possible price for shareholders [1]. - Concerns include the fairness of the sales process and potential conflicts of interest that may limit superior competing offers [1]. - Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief and benefits for shareholders [1]. Group 2: Legal Representation - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions on behalf of defrauded investors [1]. - The firm operates on a contingent fee basis, meaning shareholders would not be responsible for out-of-pocket legal fees or expenses [1].

Core Viewpoint - Xylem Inc, a leading global water technology company, is facing challenges despite reporting strong quarterly earnings, with revised forecasts falling short of market expectations [2][3][4]. Financial Performance - Xylem reported fourth-quarter earnings per share of $1.42, slightly above the consensus estimate of $1.41 [2][6]. - Quarterly sales reached $2.397 billion, surpassing the expected $2.374 billion [3][6]. - The company's forecast for fiscal year 2026 adjusted earnings per share is between $5.35 and $5.56, below market estimates of $5.56 [3]. - Xylem anticipates sales between $9.1 billion and $9.2 billion, falling short of the expected $9.331 billion [3]. Market Reaction - Following the earnings report, Xylem's shares fell by 2.1% to $126.24 [4][6]. - Goldman Sachs set a revised price target of $158 for Xylem, down from a previous target of $175, indicating a potential increase of about 24.64% from the current stock price of $126.77 [2][6]. Stock Performance - Currently, Xylem is trading at $126.77, reflecting a decrease of 1.67% or $2.15 [5]. - The stock has fluctuated between $125.92 and $131.73 on the day, with a yearly high of $154.27 and a low of $100.47 [5]. - The company's market capitalization is approximately $30.86 billion, with a trading volume of 2,951,416 shares on the NYSE [5].

Core Viewpoint - Bio-Techne Corporation is a significant entity in the biotechnology sector, focusing on innovative tools and solutions for life sciences research and clinical diagnostics, competing with major players like Thermo Fisher Scientific and Danaher Corporation [1] Financial Performance - On February 4, 2026, Citigroup upgraded Bio-Techne's stock to a "Buy" rating at approximately $68.89, raising the price target from $70 to $80, indicating confidence in the company's growth potential [2] - Bio-Techne recently held its Q2 2026 earnings call, providing insights into its financial performance, revenue, profit margins, and strategic initiatives, which are crucial for understanding the company's current position and future outlook [3] Stock Performance - Currently, Bio-Techne's stock (TECH) is priced at $68.77, reflecting a 6.41% increase or $4.14, with a daily trading range between $61.70 and $69.92 [4] - Over the past year, the stock has fluctuated, reaching a high of $79.28 and a low of $46.01, indicating the dynamic nature of the stock market [4] Market Capitalization and Trading Volume - Bio-Techne's market capitalization is approximately $10.72 billion, with a trading volume of 3.59 million shares, reflecting the company's size and investor interest in its stock [5]

Core Insights - Agilent Technologies, Inc. is a global leader in life sciences, diagnostics, and applied chemical markets, providing a comprehensive range of instruments, software, services, and consumables for laboratory workflows [1] - UBS has maintained a "Buy" rating for Agilent, raising its price target from $170 to $180, indicating confidence in the company's growth potential [2][5] - Agilent's stock price is currently $153.60, reflecting a 1.55% increase, with significant volatility observed over the past year [4][5] Financial Performance - Agilent's recent Q4 2025 earnings call highlighted key figures such as CEO Padraig McDonnell and CFO Adam Elinoff, showcasing the company's financial performance and strategic direction [3] - The stock has fluctuated between $150.47 and $153.60 on the current trading day, with a market capitalization of approximately $43.55 billion [4][5] - Over the past year, Agilent's stock reached a high of $153.84 and a low of $96.43, indicating notable volatility in its stock performance [4][5] Market Position - Agilent competes with major players like Thermo Fisher Scientific and Danaher Corporation in the life sciences and diagnostics sectors, highlighting its significant presence in the industry [1]